ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $209.91 million. The enterprise value is $76.76 million.
| Market Cap | 209.91M |
| Enterprise Value | 76.76M |
Important Dates
The last earnings date was Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 134.56 million shares outstanding. The number of shares has increased by 25.44% in one year.
| Current Share Class | 134.56M |
| Shares Outstanding | 134.56M |
| Shares Change (YoY) | +25.44% |
| Shares Change (QoQ) | +92.64% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 37.45% |
| Float | 77.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.38 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.21 |
| Quick Ratio | 6.95 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -57.62 |
Financial Efficiency
Return on equity (ROE) is -74.17% and return on invested capital (ROIC) is -41.55%.
| Return on Equity (ROE) | -74.17% |
| Return on Assets (ROA) | -36.76% |
| Return on Invested Capital (ROIC) | -41.55% |
| Return on Capital Employed (ROCE) | -55.64% |
| Weighted Average Cost of Capital (WACC) | 7.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.07M |
| Employee Count | 43 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +167.70% in the last 52 weeks. The beta is 0.45, so ALXO's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +167.70% |
| 50-Day Moving Average | 1.82 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 31.62 |
| Average Volume (20 Days) | 1,062,016 |
Short Selling Information
The latest short interest is 1.38 million, so 1.03% of the outstanding shares have been sold short.
| Short Interest | 1.38M |
| Short Previous Month | 2.21M |
| Short % of Shares Out | 1.03% |
| Short % of Float | 1.78% |
| Short Ratio (days to cover) | 1.42 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -87.99M |
| Pretax Income | -88.87M |
| Net Income | -88.87M |
| EBITDA | -87.35M |
| EBIT | -87.99M |
| Earnings Per Share (EPS) | -$1.34 |
Balance Sheet
The company has $140.32 million in cash and $8.51 million in debt, with a net cash position of $131.81 million or $0.98 per share.
| Cash & Cash Equivalents | 140.32M |
| Total Debt | 8.51M |
| Net Cash | 131.81M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 151.35M |
| Book Value Per Share | 1.12 |
| Working Capital | 125.39M |
Cash Flow
In the last 12 months, operating cash flow was -$78.13 million and capital expenditures -$202,000, giving a free cash flow of -$78.33 million.
| Operating Cash Flow | -78.13M |
| Capital Expenditures | -202,000 |
| Depreciation & Amortization | 645,000 |
| Net Borrowing | -2.67M |
| Free Cash Flow | -78.33M |
| FCF Per Share | -$0.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALXO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.44% |
| Shareholder Yield | -25.44% |
| Earnings Yield | -42.61% |
| FCF Yield | -37.56% |
Analyst Forecast
The average price target for ALXO is $4.60, which is 194.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.60 |
| Price Target Difference | 194.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |